Table 2.
Diagnostic performance of T-Track® TB and QFT-Plus to discriminate active TB patients from non-infected controls.
| Assay | Sensitivity n/N (%) [95% CI] |
Specificity n/N (%) [95% CI] |
Accuracy n/N (%) [95% CI] |
Invalid Rate n/N (%) |
Inconclusive Rate n/N (%) |
|---|---|---|---|---|---|
| T-Track® TB 1 | 168/177 (94.9%) [90.5–97.4] |
151/161 (93.8%) [88.8–96.7] |
319/338 (94.4%) [91.3–96.4] |
4/344 (1.16%) |
2/344 (0.58%) |
| QFT-Plus 2 | 150/178 (84.3%) [78.2–88.9] |
n.d. 3 | n.d. 3 | 0/342 (0.00%) |
1/342 (0.29%) |
1 After exclusion of four invalid and two inconclusive T-Track® TB results, performance was evaluated on 177 active TB and 161 control samples (Figure S1). 2 After exclusion of one indeterminate and two missing QFT-Plus results, performance was evaluated on 178 active TB and 163 control samples (Figure S2). 3 Specificity and accuracy of the QFT-Plus assay cannot be determined in the current study design because QFT-Plus-negative result was defined as inclusion criterion for non-infected controls. Abbreviations: CI, confidence interval; n.d., not determined; QFT-Plus, QuantiFERON®-TB Gold Plus; TB, tuberculosis.